Northern Biologics merges with our client Mosaic Biomedicals as Versant and Celgene increase involvement

Northern Biologics, a Canadian biotech, merged with Mosaic Biomedicals, a Barcelona company and Metrix Partners client, in December 2016. The combined company aimed to become a global cancer company and to start human testing of its lead candidate, MSC-1, in 2017.

Northern Biologics merger with Mosaic Biomedicals

The deal

According to Fierce Biotech, Versant Ventures expanded its Series A investment in Northern Biologics as part of the merger. Celgene exercised an option to acquire certain rights to the MSC-1 programme under an existing agreement. With these commitments, the company had full funding for early clinical development of MSC-1, as well as its preclinical programmes.

Northern Biologics had launched in December 2014 with $45M in committed funding from Versant and Celgene. The merger announcement described the deal as transformative, bringing an expanded pipeline, new financing and leadership hires.

About Mosaic Biomedicals

Mosaic Biomedicals was founded in 2013 in Barcelona to develop personalised cancer treatments. Its lead programme was MSC-1, a humanised antibody against leukaemia inhibitory factor (LIF). Investment from Versant and Caixa Capital Risc had taken MSC-1 close to clinical trials before the merger.

Why the merger made sense

Mosaic brought a clinical-ready antibody and scientific expertise in LIF. Northern Biologics brought capital, a drug development team and its own pipeline of antibodies targeting the tumour microenvironment. The combination gave MSC-1 the resources to enter the clinic and gave Northern a lead asset.

Five lessons from the Mosaic Biomedicals merger

  1. Mergers can fund the next stage. Combining with a well-funded partner can be faster than raising a large round alone.
  2. Shared investors ease deals. Versant’s position in both companies helped align interests.
  3. Valuation needs a clear method. Relative value of each pipeline must be agreed and supported by data.
  4. Cross-border mergers need structure. Tax, legal and IP transfer between Spain and Canada require careful planning.
  5. Founders’ roles should be defined. Scientific founders need clear roles in the combined company.

What founders should prepare for a biotech merger

  • Accounts reconciled to the statutory filings.
  • A full IP and licence inventory.
  • A cap table with all instruments and investor rights.
  • Programme budgets and data packages.
  • Tax analysis of the transaction structure.

What happened next

MSC-1 entered the clinic in 2018 at Memorial Sloan Kettering. In 2020, Boehringer Ingelheim acquired Northern’s preclinical pipeline and an AstraZeneca subsidiary acquired MSC-1. The merger with Mosaic Biomedicals set up both exits.

Metrix Partners in life sciences

Metrix has worked with Mosaic Biomedicals since its early stage and supports other life sciences clients such as AELIX Therapeutics and Accure Therapeutics.